Physician profile
Michael Jon Cox
NPI 1245441690
$7,838.97
in general payments reported to CMS, 2019-2025
26 companies · $672 in 2025
The $672 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,839 · 2020: $3,354 · 2021: $319 · 2022: $1,159 · 2023: $203 · 2024: $294 · 2025: $672.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,168.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,914.11 | 2019-2020 | |
| Boston Scientific Corporation | $1,087.81 | 2019-2023 | Lithovue |
| Abbvie INC. | $379.50 | 2020-2025 | Botox |
| Sumitomo Pharma America, INC. | $274.39 | 2024-2025 | Orgovyx, Gemtesa |
| Astellas Pharma US INC | $252.83 | 2019-2025 | Xtandi, Myrbetriq |
| Pfizer INC. | $157.82 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $123.86 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Allergan, INC. | $74.80 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $73.61 | 2019-2025 | |
| Coloplast Corp | $65.74 | 2023-2025 | Porges Coloplast |
| Endo Pharmaceuticals INC. | $64.16 | 2020-2024 | Xiaflex |
| Amgen INC. | $50.26 | 2019-2021 | |
| Laborie Medical Technologies Corp. | $42.85 | 2023-2025 | |
| Janssen Biotech, INC. | $39.72 | 2019 | |
| Novartis Pharmaceuticals Corporation | $36.80 | 2022-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $30.85 | 2023-2024 | Prolaris |
| Verity Pharmaceuticals INC. | $24.83 | 2025 | Tlando |
| Dendreon Pharmaceuticals LLC | $24.44 | 2025 | Provenge |
| Endo USA, INC. | $20.63 | 2025 | Xiaflex |
| Olympus America INC. | $19.64 | 2025 | Itind System |
| Telix Pharmaceuticals | $19.27 | 2025 | Illuccix |
| Urogen Pharma, INC. | $16.46 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $15.26 | 2021 | |
| Innovation Technologies INC | $13.19 | 2024 | Irrisept |
| Foundation Medicine, INC. | $12.34 | 2022 | |
| Travere Therapeutics, INC. | $3.80 | 2019-2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Cox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.